Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Israeli Stocks: Bezeq, Teva Pharmaceutical, I.T.G.I., Paz Oil

Aug. 1 (Bloomberg) -- Israel’s TA-25 Index dropped the most since June 15, sliding 2 percent to 1,199.45 at the 4:30 p.m. close in Tel Aviv. Investors traded about 1.41 billion shekels ($410.2 million) in shares and convertible securities, according to Tel Aviv Stock Exchange data.

The following stocks rose or fell today. Symbols are in parentheses.

Bezeq The Israeli Telecommunication Corp. (BEZQ IT) retreated 2 percent to 8.24 shekels, the lowest since November 2009. The country’s largest communications company is scheduled to report second-quarter results after the close. Bezeq may say net income fell to 583.5 million shekels from 638 million shekels a year earlier, according to the median estimate of six analysts in a Bloomberg survey.

I.T.G.I. Medical Ltd. (ITGI IT) increased the most since June 13, soaring 11 percent to 0.322 shekel. The maker of vascular products signed a four-year agreement with Beijing Xinchengwanda Trading Co. to distribute its AneuGraft Dx cardiac stent in China.

Paz Oil Co. (PZOL IT) slumped to the lowest since July 2010, dropping 4.1 percent to 509.30 shekels. The maker of petroleum-based products said government plans to lower gasoline prices may have a “significant impact” on its profit.

Teva Pharmaceutical Industries Ltd. (TEVA IT) plunged 7.2 percent to 149 shekels, the biggest loss since October 2008. The world’s largest generic drugmaker said its laquinimod experimental multiple sclerosis drug failed to meet the main goal of a clinical trial.

To contact the reporter on this story: Sharon Wrobel in Tel Aviv at swrobel4@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.